Loading stock data…
$11.84-0.15 (-1.24%)
Obsidian Therapeutics, Inc.
| Metric (USD) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $0 | $0 |
| Gross Profit | — | — |
| Operating Income | -$20.28M↑ | -$26.60M |
| Net Income | -$19.63M↑ | -$24.99M |
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for adva...